此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Unilateral and Bilateral Resistance Training in Hypertension

2026年8月5日 更新者:Ceyhun Topcuoglu、Hacettepe University

Comparison of the Effects of Unilateral and Bilateral Resistance Training on Heart Rate Variability, Muscle Strength, and Functional Capacity in Individuals With Hypertension: A Randomized Controlled Trial

Hypertension is associated with autonomic nervous system dysfunction, reduced muscle strength, and impaired functional capacity, all of which contribute to increased cardiovascular risk and decreased quality of life. Resistance training is recommended as a non-pharmacological intervention for hypertension; however, it remains unclear whether unilateral and bilateral resistance training produce different physiological adaptations, particularly regarding cardiac autonomic function.

This randomized controlled trial aims to compare the effects of unilateral and bilateral resistance training on heart rate variability (HRV), muscle strength, and functional capacity in adults with hypertension. Eligible participants aged 40-75 years with a confirmed diagnosis of hypertension will be randomly allocated to one of three groups: a unilateral resistance training group, a bilateral resistance training group, or a control group. Randomization will be performed using a computer-generated block randomization procedure with sex stratification to ensure balanced group allocation.

Participants in the two intervention groups will complete a supervised 12-week resistance training program, performed twice weekly at an intensity of 60-70% of one-repetition maximum (1RM). The unilateral training group will perform exercises using one limb at a time, whereas the bilateral training group will perform the same exercises simultaneously with both limbs. The control group will receive no structured exercise intervention during the study period but will receive general information regarding the benefits of physical activity.

Assessments will be conducted at baseline and after the 12-week intervention. The primary outcome will be heart rate variability measured using a Polar H10 heart rate sensor and Elite HRV software. Secondary outcomes will include peripheral muscle strength assessed by one-repetition maximum testing, functional capacity assessed using the Six-Minute Walk Test and the Glittre Activities of Daily Living Test, and blood pressure measured using a sphygmomanometer.

The findings of this study are expected to provide evidence regarding the optimal resistance training strategy for improving autonomic function and physical performance in individuals with hypertension, thereby supporting the development of safer and more individualized exercise prescriptions.

研究概览

详细说明

Hypertension is one of the leading modifiable risk factors for cardiovascular disease and is strongly associated with autonomic nervous system dysfunction. Increased sympathetic activity and reduced parasympathetic activity contribute to impaired cardiovascular regulation, which can be assessed non-invasively through heart rate variability (HRV). Reduced HRV has been associated with increased cardiovascular morbidity and mortality. In addition to autonomic dysfunction, individuals with hypertension frequently exhibit reduced muscle strength, impaired functional capacity, and limitations in daily physical activities.

Resistance training is widely recommended as a safe and effective non-pharmacological intervention for hypertension because it improves blood pressure control, muscular fitness, and overall physical function. Although both unilateral and bilateral resistance training are commonly prescribed, their physiological effects may differ. Unilateral resistance exercises generally involve a smaller active muscle mass, potentially resulting in lower cardiovascular stress while maintaining local muscular adaptations. In contrast, bilateral resistance exercises recruit a larger muscle mass and may induce greater cardiovascular and hemodynamic responses. Despite these theoretical differences, evidence directly comparing their effects on cardiac autonomic regulation in individuals with hypertension remains limited.

The primary objective of this randomized controlled trial is to compare the effects of unilateral and bilateral resistance training on cardiac autonomic function assessed by HRV in adults with hypertension. Secondary objectives include evaluating changes in peripheral muscle strength, functional capacity, activities of daily living, and blood pressure following a supervised resistance training program.

Adults aged 40 to 75 years with a physician-confirmed diagnosis of hypertension who are able to participate safely in resistance exercise will be recruited from Munzur University and Tunceli State Hospital. After providing written informed consent, eligible participants will be randomly assigned to one of three groups using a computer-generated block randomization procedure with sex stratification:

Unilateral Resistance Training Group Bilateral Resistance Training Group Control Group

Participants allocated to the intervention groups will complete a supervised 12-week resistance training program performed twice weekly. Exercise intensity will be prescribed at 60-70% of one-repetition maximum (1RM). Both intervention groups will perform the same resistance exercises, including leg press, knee extension, leg curl, seated row, and chest press. The unilateral group will perform each exercise separately with the right and left limbs, whereas the bilateral group will perform the exercises simultaneously using both limbs. Each exercise session will consist of 2-3 sets of 8-12 repetitions with at least one minute of rest between sets. Training loads will be progressively increased when participants are able to perform more than 20 repetitions with a perceived exertion below 3 on the Modified Borg Scale.

Participants in the control group will not receive supervised resistance training during the 12-week intervention period but will receive standardized education regarding the health benefits of regular physical activity. Following study completion, participants in the control group will be offered the exercise intervention if the training program is demonstrated to be beneficial.

Outcome assessments will be performed at baseline and after completion of the 12-week intervention. HRV will be measured using a Polar H10 heart rate sensor connected to the Elite HRV application. Measurements will be obtained before exercise, immediately after exercise, and during the recovery period. Time-domain variables, including RMSSD, SDNN, pNN50, and mean RR interval, as well as frequency-domain variables, including total power, LF power, HF power, LF/HF ratio, LF peak frequency, and HF peak frequency, will be analyzed.

Peripheral muscle strength will be evaluated using one-repetition maximum testing for leg press, knee extension, leg curl, seated row, and chest press. Functional capacity will be assessed using the Six-Minute Walk Test (6MWT), while functional performance in activities of daily living will be evaluated using the Glittre Activities of Daily Living Test (Glittre-ADL). Resting and exercise blood pressure will be measured using a validated sphygmomanometer.

The study hypothesis is that unilateral resistance training will produce improvements in HRV, muscle strength, and functional capacity comparable to or greater than bilateral resistance training while imposing lower cardiovascular stress. The findings are expected to provide evidence supporting individualized resistance exercise prescription for individuals with hypertension and contribute to the optimization of exercise-based cardiovascular rehabilitation programs.

研究类型

介入性

注册 (估计的)

54

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

描述

Inclusion Criteria:

  • Adults aged 40 to 75 years.
  • Physician-confirmed diagnosis of hypertension.
  • Medically stable and able to safely participate in a supervised resistance training program.
  • Able to understand the study procedures and provide written informed consent.

Exclusion Criteria:

  • Presence of cardiovascular diseases other than hypertension.
  • Neurological disorders.
  • Psychiatric disorders.
  • Orthopedic conditions limiting participation in resistance exercise.
  • Any other systemic disease that may interfere with study participation.
  • Cognitive impairment or psychological conditions preventing completion of the assessments.
  • History of recent surgery or medical conditions contraindicating exercise.
  • Inability or unwillingness to comply with the study protocol.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Unilateral Resistance Training Group
Participants will receive a supervised unilateral resistance training program twice weekly for 12 weeks. Training intensity will be set at 60-70% of one-repetition maximum (1RM). Exercises will include leg press, knee extension, leg curl, seated row, and chest press, performed separately with the right and left limbs. Each session will consist of 2-3 sets of 8-12 repetitions with at least 1 minute of rest between sets. Training load will be progressively increased according to participants' performance and perceived exertion.
Participants will complete a supervised unilateral resistance training program twice weekly for 12 weeks. Exercise intensity will be prescribed at 60-70% of one-repetition maximum (1RM). Exercises include leg press, knee extension, leg curl, seated row, and chest press performed separately with the right and left limbs. Each session consists of 2-3 sets of 8-12 repetitions with at least 1 minute of rest between sets. Training loads will be progressively increased based on participants' performance and perceived exertion using the Modified Borg Scale.
实验性的:Bilateral Resistance Training Group
Participants will receive a supervised bilateral resistance training program twice weekly for 12 weeks. Exercise intensity will be prescribed at 60-70% of one-repetition maximum (1RM). The training program will include leg press, knee extension, leg curl, seated row, and chest press performed simultaneously with both limbs. Each exercise will be completed for 2-3 sets of 8-12 repetitions with at least 1 minute of rest between sets. Training intensity will be progressively increased according to participants' performance and perceived exertion.
Participants will complete a supervised bilateral resistance training program twice weekly for 12 weeks. Exercise intensity will be prescribed at 60-70% of one-repetition maximum (1RM). Exercises include leg press, knee extension, leg curl, seated row, and chest press performed simultaneously with both limbs. Each session consists of 2-3 sets of 8-12 repetitions with at least 1 minute of rest between sets. Training loads will be progressively increased according to participants' performance and perceived exertion using the Modified Borg Scale.
无干预:Control Group
Participants assigned to the control group will not receive supervised resistance training during the 12-week study period. They will receive standardized education regarding the health benefits of regular physical activity. After study completion, participants will be offered the exercise program if the intervention is shown to be beneficial.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Muscle Strength
大体时间:Baseline and Week 12
Muscle strength will be assessed using one-repetition maximum (1RM) testing for leg press, knee extension, leg curl, seated row, and chest press exercises.
Baseline and Week 12
Functional Capacity
大体时间:Baseline and Week 12
Functional capacity will be evaluated using the Six-Minute Walk Test (6MWT). Walking distance and physiological responses will be recorded before and after the intervention.
Baseline and Week 12
RMSSD
大体时间:Baseline and Week 12
Change in the root mean square of successive differences (RMSSD) measured using heart rate variability analysis. RMSSD is reported in milliseconds (ms). Minimum value: 0 ms. There is no fixed maximum value. Higher values indicate greater parasympathetic activity and improved cardiac autonomic function (better outcome).
Baseline and Week 12
SDNN
大体时间:Baseline and Week 12
Change in the standard deviation of normal-to-normal intervals (SDNN) measured using heart rate variability analysis. SDNN is reported in milliseconds (ms). Minimum value: 0 ms. There is no fixed maximum value. Higher values indicate greater overall heart rate variability and improved cardiac autonomic function (better outcome).
Baseline and Week 12
pNN50
大体时间:Baseline and Week 12
Change in the percentage of successive normal-to-normal intervals differing by more than 50 ms (pNN50). The outcome is expressed as a percentage (%). Minimum value: 0%. Maximum value: 100%. Higher values indicate greater parasympathetic activity (better outcome).
Baseline and Week 12
Mean RR Interval
大体时间:Baseline and Week 12
Change in mean RR interval measured using heart rate variability analysis. The outcome is expressed in milliseconds (ms). Minimum value: 0 ms. There is no fixed maximum value. Higher values generally indicate a lower resting heart rate and improved autonomic regulation (better outcome).
Baseline and Week 12
Total Power
大体时间:Baseline and Week 12
Change in total power measured using heart rate variability analysis. The outcome is expressed in milliseconds squared (ms²). Minimum value: 0 ms². There is no fixed maximum value. Higher values indicate greater overall heart rate variability (better outcome).
Baseline and Week 12
LF Power
大体时间:Baseline and Week 12
Change in low-frequency (LF) power measured using heart rate variability analysis. The outcome is expressed in milliseconds squared (ms²). Minimum value: 0 ms². There is no fixed maximum value. Higher values generally indicate greater autonomic modulation.
Baseline and Week 12
HF Power
大体时间:Baseline and Week 12
Change in high-frequency (HF) power measured using heart rate variability analysis. The outcome is expressed in milliseconds squared (ms²). Minimum value: 0 ms². There is no fixed maximum value. Higher values indicate greater parasympathetic activity (better outcome).
Baseline and Week 12
LF Peak
大体时间:Baseline and Week 12
Change in low-frequency peak (LF Peak) measured using heart rate variability analysis. The outcome is expressed in hertz (Hz). Minimum value: 0 Hz. There is no fixed maximum value.
Baseline and Week 12
HF Peak
大体时间:Baseline and Week 12
Change in high-frequency peak (HF Peak) measured using heart rate variability analysis. The outcome is expressed in hertz (Hz). Minimum value: 0 Hz. There is no fixed maximum value.
Baseline and Week 12

次要结果测量

结果测量
措施说明
大体时间
Activities of Daily Living
大体时间:Baseline and Week 12
Change in activities of daily living performance assessed using the Glittre Activities of Daily Living (Glittre ADL) Test. The outcome is the total time required to complete the Glittre ADL Test, measured in seconds (s). Minimum value: 0 seconds. There is no fixed maximum value. Lower completion times indicate better functional performance in activities of daily living (better outcome), whereas higher completion times indicate poorer functional performance (worse outcome).
Baseline and Week 12
Blood Pressure
大体时间:Baseline and Week 12
Systolic and diastolic blood pressure will be measured using a validated sphygmomanometer before exercise, immediately after exercise, and 30 minutes after exercise during the baseline and post-intervention assessments.
Baseline and Week 12

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月22日

初级完成 (估计的)

2026年9月25日

研究完成 (估计的)

2026年10月1日

研究注册日期

首次提交

2026年8月2日

首先提交符合 QC 标准的

2026年8月5日

首次发布 (实际的)

2026年8月7日

研究记录更新

最后更新发布 (实际的)

2026年8月7日

上次提交的符合 QC 标准的更新

2026年8月5日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 2026/8-21

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅